Investors thrive on foresight. To stay ahead, you need insights into emerging and future trends, disruptive technologies, and market dynamic

Investors
Solve your biggest challenges at HLTH Europe 2025
At HLTH Europe, we understand the complexities of investing in healthcare innovation. Whether you’re refining your thesis and focus areas, looking to increase deal flow, supporting your portfolio, or building your network and reputation, our event is designed to meet your needs.
Here's how we help:
Expand deal flow: Meet high-potential startups and collaborate with a global network of investors. Our complimentary curated networking programme, Investor Connect, not only matches you with Europe’s most promising startup founders or other investors for 15-minute, 1:1 meetings, but also guarantees you access to the exclusive Investor Lounge (with comfy seating & power points for informal meetings between sessions), a networking brunch and a speed networking breakfast with underrepresented founders.
Support portfolio success: Connect your companies with partners, customers, and growth resources
Build your network: Engage with leaders across healthcare, including potential LPs, corporates, providers and policymakers
Gain market clarity: Access cutting-edge insights to shape your investment strategies and focus areas
We solve your (business) problems
Refining your investment thesis with market insights
Your challenges:
Understanding complex, fast-changing and diverse healthcare markets
Identifying sectors, verticals and geographies with the greatest growth potential
How HLTH Europe solves this:
Expert content: 50+ hours of sessions with 300+ industry visionaries, exploring critical topics like regulation in health tech, demystifying payers, the implementation of the European Health Data Space and how to effectively scale in diverse European markets
Direct access to experts: Speak with decision-makers from providers, payers, healthtech, pharma, and more for real-world perspectives
Trend spotting: Stay ahead of the curve with discussions on everything from precision medicine and longevity, to wearables, GLP-1s and the silvertech revolution
Expanding your deal flow pipeline
HLTH Europe helps you not only meet promising founders, but also connect with the global investor community to support deal-sharing, and follow-on referrals.
Your challenges:
Finding startups that fit your investment criteria
Building relationships for syndication, deal-sharing and follow-on deals
How HLTH Europe solves this:
Investor Connect: A free, curated matchmaking program that puts you in the driving seat of selecting suitable founders to meet based on criteria like stage, market, and category. PLUS access to the exclusive Investor Lounge (with comfy seating & power points for informal meetings between sessions), a networking brunch and a speed networking breakfast with underrepresented founders.
500+ Startup founders: Meet a wide range of high-potential startups, from early-stage innovators to growth-stage success stories like Oura and Doctolib
300+ Investors: Connect and collaborate with global VCs, family offices, corporate investors, PE and institutional investors
Supporting your portfolio to drive returns
Portfolio success depends on more than just funding. Operational know-how, market insights, and key connections are critical to helping your companies grow. Bring your portfolio to HLTH Europe on reduced rate tickets to turbocharge their success.
Your challenges:
Providing meaningful support to portfolio companies
Introducing them to potential customers, partners, and growth opportunities
How HLTH Europe solves this:
Growth opportunities: Help your portfolio founders connect with other investors (e.g. through Investor Connect) for follow-on deals, corporates, government leaders, regulators and providers
Startup support: Exclusive access to founder-only sessions on effectively scaling healthcare startup operations, the road to €100m revenue and how to raise 8 figures
Visibility: Facilitate participation in pitch opportunities and exhibition space to raise their profile and introduce them to prospective customers
Meeting prospective LPs
Fundraising is a constant need, whether you’re launching a new fund or expanding an existing one. Reaching potential LPs and building trust can be a challenge.
Your challenges:
Finding the right LPs at the right time.
Differentiating your fund from the competition.
How HLTH Europe solves this:
Engage potential LPs: Meet institutional investors, family offices, and high-net-worth individuals at the event
Build trust through networking: Use informal spaces like the Investor Lounge to foster meaningful connections (only available to those taking part in Investor Connect)
Raising your profile and reputation
An investor’s reputation is their currency. Credibility and visibility attract deals, funds, partnerships, and trust.
Your challenges:
Building a public profile that attracts founders, LPs, and collaborators
Showcasing your expertise and successes
How HLTH Europe solves this:
Speaking opportunities: Share your insights on panels or stages to position yourself as a thought leader. Apply here.
Sponsorship opportunities: From booths & meeting rooms, to breakfasts and boat rides we have a multitude of opportunities to get you in front of the right people. Take a look here.
Media exposure: Leverage the presence of media and analysts to amplify your voice and success stories, or submit your news to the announcements stage
Global reach: Engage with 5,000+ decision-makers to elevate your professional profile
2025 investor agenda highlights include:
Missing links: Why VCs and providers need better links
There’s a temptation to declare providers as mysterious - their wants and needs an enigma. But speak to provider leaders, and they know what they want, and what challenges they have to solve. As one put it to us: “Don’t bring me solutions to problems I didn’t know I have”.
With VCs sat on more unused capital than any time in recent memory, is now the time for better links between investors and providers? After all, when the pool of customers is limited, understanding their needs becomes of paramount importance.
M&A: Turning the tide in a turbulent market
Being a headline writer in European tech has been a depressing job for the last few years.
But here at HLTH Europe we say no to negativity.
Yes, the waters have been choppy. Yes, the numbers are down. But there are still reasons to celebrate. Companies to champion. Success stories and triumphs.
HLTH started in Las Vegas, and we know that when the chips are down, you have two choices. Leave the party or double down. And we choose to double down. To celebrate the wins. Because more are coming. We'd bet the house on it.
Nothing about us without us: Because nobody knows more about patients than patients
There are many crimes in healthtech marketing. We won’t name them all, for fear of alienating literally everyone. But top of the list is the term "patient-centric" when the product in question has not, in fact, been developed with patients.
Boil healthcare down to its bare minimum and it’s about keeping patients alive and healthy. And yet so often, they’re not in the room when decisions are made.
It’s time to flip that script. To give patients a seat at the table, after all, who better to share the future of healthcare than those living it every day?
So, you want to be a founder?
Are you getting too much sleep? A little too much free time on the weekends? Enjoying a splendid work-life balance?
Well, have we got the solution for you! Become a founder, and you'll receive the following benefits:
- An almost limitless amount of work!
-Free anxiety!
-Nightly 3am existential crises!
All that for less money than you're on now, and in a more difficult market than we've seen in years!
Jokes aside, being a founder is a tough gig.
Whether you're going solo, pairing up with a trusted ally, or even going into it as a group, there's never an easy path to success.
Hear all about the trials, tribulations but also the triumphs from our panel of founders who've made the impossible, possible.
Health meets wealth: What next for Private Equity in healthcare?
In 2021, Private Equity, like every other investment sector, surged into healthcare, investing $50.97 billion in healthtech. By 2023 this had dropped back down to $9.18 billion, more in line with 2019’s figures.
This may all seem quite doom-laden, but there is light at the end of the tunnel. Across the healthtech landscape there are numerous opportunities. Traditionally PE has focused on investing in large, high-growth healthcare technology companies.
But for those funds looking for companies with the potential for double-digit growth, the midtier of healthtech offers an intriguing opportunity.
What areas of healthtech are ready for a new wave of PE funding? What emerging trends or technologies within healthtech could catalyse a resurgence in Private Equity investment?
Organisational transformation: Slow is smooth and smooth is fast
There's a saying amongst Navy SEALS - "Slow is smooth and smooth is fast". The idea that doing things methodically and deliberately may feel like slower progress is made, but ultimately gets you there faster.
When it comes to transformation in healthcare, we've mastered the slow bit. In fact we're arguably the world's leading sector when it comes to slow transformation. Smooth? Not so much.
We are notorious for our slow adoption of innovation. Some of this is unavoidable - healthcare regulations are often written in blood.
But we cannot hide behind this. Cultural resistance, ingrained systems and a lack of short-term capacity to do things that would free up long-term capacity.
To truly transform, organisations must evolve into "smooth operators" – agile, responsive, and forward-thinking. But is this even possible in a sector where slow is slow and smooth is a pipedream?
Show me the money: New pathways, same pitfalls
The year is 2021.
Events are back in person for the first time in 18 months.
And you've only just picked up your badge when someone sidles up and shouts 'DiGA' in your ear.
So this is the "new normal".
In Germany tested health apps can be prescribed as part of statutory health insurance since the Digital Care Act came into force on December 19, 2019.
It was seen as a watershed moment in European healthtech, and indeed healthcare, history.
Across Europe Minister Jens Spahn was lauded as a visionary. This was the moment. It was all going to be OK. One area of healthtech had a viable, reliable, certifiable route to getting paid. To making profit. Across Europe, VC pockets quivered with anticipation.
Other nations raced to fall into line. And yet just a few years later, and following a spate of DTx companies going under in Germany and across the globe, DTx has lost some of its shine.
Where once the pathway to getting paid looked clearer, storm clouds have gathered again.
Pitch Perfect: The Do's & Don'ts of pitch deck building
Googling "Pitch deck advice" is about as effective as Googling "What is this rash?". You’ll get a hundred different opinions, each more convincing than the last. Soon your deck is the length of a novel and the file is too big to share by email. But it is written. And off it goes.
Across town, in an office that isn't quite as nice as the outside would have you believe, a tired VC investment manager opens their inbox.
Amongst the "pls fix" emails there are a plethora of pitch decks. Their weary eyes scan each slide as the cleaner lifts their legs to vacuum under them.
Too much text. Not enough narrative. Unrealistic figures. Is that really the TAM? Crumbs, is that really the time? Best head home, another 100 decks to review tomorrow.
But help is at hand, in the form of our All-Star VC panel, who will guide you through the needs and wants, dos and don'ts of building a deck to smash your funding goals.
What's hot what's not: Investor panel
Is this the same title as last year? Yes. Yes it is.
Was it the most saved track session last year? Yes, yes it was.
Is reusing your own titles lazy? Yes, yes it is. But we’ve written 90 of these now, and our brains hurt.
It can often feel like there are more pillars in healthtech than there are in Athens. From robotics to RPM, biomarkers to blockchain, AI to automation. We’re awash with pillars, verticals and sectors.
Every investment fund will have their own thesis. But with just 9% of European VC deals making the coveted 10x return on investment, what to pick in a market so broad is an unrelenting challenge. Go all in on AI? Stick to your specialised silos? Double down on diagnostics?
Fear not though, we’ve pulled together an all-star panel of VCs, the great and the good, to guide you through it.
On mute: Has telehealth peaked?
Quite a lot of things peaked in the COVID pandemic. Banana bread baking. Sex toy sales. Zoom’s share price. All of which, on reflection, make sense. Except the banana bread.
Also riding high were the telehealth startups. Wild valuations, IPOs, huge rounds. This was telehealth’s big moment, and it was determined to seize it. All of which, on reflection, makes sense. Except the IPOs.
But as it turns out, levels of growth heavily dependent on nobody being allowed outside are not overly sustainable when people are, once again, allowed outside.
But since 2022 the growth of telehealth has dropped off significantly. Some of the biggest names are long gone. Down rounds abound. The EU is likely to remove €1 billion in funding for the EU4Health programme that has supported telehealth, and other initiatives, since 2021.
Has it now found its rightful size? Or is this just a temporary muting?
2025 speakers include:

Alyssa Jaffee
Partner
7wireVentures
USA

Frédérique Dame
General Partner
GV
USA

Hal Paz
Operating Partner
Khosla Ventures
USA

Heyo Kroemer
CEO
Charité - University Medicine Berlin
Germany

Nina Rognon
Innovation Platform Executive Director
AP-HP
France

William Taranto
President, Founder & General Partner
Merck Global Health Innovation Fund
USA